Patent application EP19305692A (EP), filed 2019-05-29
Publication number: EP3744312A1
Title: GREEN TEA CATECHINS EUTECTIC SYSTEM
Abstract: [0001]    The present invention concerns a stable liquid eutectic system of an active ingredient chosen from catechins, anthocyanins, and procyanidins, and pharmaceutical, dermo-cosmetic or nutraceutical compositions comprising said eutectic system.
IPC codes: A23F   3/    14            A I
A61K  31/   353            A I
A61K  36/    82            A I
A61K  47/    18            A I
A61K  47/    20            A I
A61K   9/    00            A I
A61K   9/    08            A I
A61Q  19/    08            A I
A61K  31/    14            A I
A61K   8/    41            A I
A61K   8/  9789            A I
Claims: number: 1
text: A stable liquid eutectic system consisting of :
number: 2
text: The stable liquid eutectic system according to claim 1, wherein the active ingredient is green tea catechins, in particularly chosen from epicatechins, epigallocatechin, epicatechin-3-gallate, epigallocatechin gallate.
number: 3
text: The stable liquid eutectic system according to claim 1 or 2, wherein the choline salt is chosen from choline chloride, choline hydroxide, choline tartrate, choline dihydrogen citrate, choline acetate, and choline sulphate.
number: 4
text: The stable liquid eutectic system according to any one of claims 1 to 3, wherein the solvent is an aprotic solvent chosen from the classes of solvents of sulfoxides, ketones, esters, amides, in particular dimethyl sulfoxide, dimethylacetamide, or a polar protic solvent chosen from water, ethanol, propylene glycol, glycerol, PEG400.
number: 5
text: The stable liquid eutectic system according to any one of claims 1 to 4, wherein said system is epigallocatechin gallate - choline chloride - an aprotic polar solvent in a molar ratio of 1.0-1.5:1:6-10.
number: 6
text: The stable liquid eutectic system according to any one of claims 1 to 4, wherein said system is epigallocatechin gallate - choline chloride - a polar protic solvent in a molar ratio of 0.25-1:1:15-50.
number: 7
text: A pharmaceutical, dermo-cosmetic or nutraceutical composition, comprising a stable liquid eutectic system as defined according to any one of claims 1 to 6, and a pharmaceutically, dermo-cosmetically or nutraceutically acceptable carrier.
number: 8
text: The pharmaceutical, dermo-cosmetic or nutraceutical composition according to claim 7, comprising:
number: 9
text: The pharmaceutical, dermo-cosmetic or nutraceutical composition according to claim 8, comprising:
number: 10
text: The pharmaceutical, dermo-cosmetic or nutraceutical composition according to claim 7-9, said composition further comprises vitamin C.
number: 11
text: The pharmaceutical composition according to any one of claims 7-10, said composition is formulated in a self-emulsifying drug-delivery system, a self-micro emulsifying drug-delivery system or an oil-free system.
number: 12
text: A pharmaceutical composition according to any one of claims 7 to 11, for its use as a medicament in the treatment of cancers, cardiovascular disorder, diabetes, neurodegenerative diseases, or dermatological diseases.
number: 13
text: A dermo-cosmetic composition according to any one of claims 7 to 10, said composition is formulated to be a semi-solid or pasty topical composition.
number: 14
text: An oral care product's composition according to any one of claims 7 to 10, said composition is formulated to be a liquid, semi-solid or pasty topical composition.
number: 15
text: A unit dose formulated with the stable liquid eutectic system according to any one of claims 1 to 6, or of the pharmaceutical, or dermo-cosmetic composition or a nutraceutical composition according to any one of claims 7-14.
number: 16
text: A food or a drink comprising a stable liquid eutectic system according to any one of claims 1-6, or a nutraceutical composition according to any one of claims 7-10, said food or drink comprises at least 10 mg of epigallocatechin gallate, from the eutectic system according to any one of claims 1 to 6.
number: 17
text: The food or the drink according to claim 16, which is a product of a coffee capsule, or a tea capsule, or any type of ready-to-use powder concentrates to be dissolved in water or other beverages, said product comprising at least 10 mg of epigallocatechin gallate per gram of product, from the eutectic system according to any one of claims 1 to 6.
Office action: search_report, dated 2020-12-02
Prior art cited: ref_id: US2014088030A1
ref_type: patent
severity: background
ref_id: EP17306623A
ref_type: patent
severity: background
ref_id: - CRIT. REV. FOOD SCI. NUTR., vol. 55, 2015, pages 792 - 80
ref_type: npl
severity: background
ref_id: - CURR. OPIN. CLIN. NUTR. METAB. CARE, vol. 11, 2008, pages 758 - 765
ref_type: npl
severity: background
ref_id: - GERIATR. GERONTOL. INT., vol. 14, 2014, pages 238 - 250
ref_type: npl
severity: background
ref_id: - INT. J. DENT. HYG., vol. 9, 2011, pages 110 - 116
ref_type: npl
severity: background
ref_id: - ISRN PREV. MED., vol. 2013, 2012, pages 975148
ref_type: npl
severity: background
ref_id: - J. AGRIC. FOOD CHEM., vol. 58, 2010, pages 1296 - 1304
ref_type: npl
severity: background
ref_id: - INT. RES. J. PHARM., vol. 3, 2012, pages 139 - 148
ref_type: npl
severity: background
ref_id: - FRONT. MICROBIOL., vol. 5, 2014, pages 434
ref_type: npl
severity: background
ref_id: - CHOW ET AL., CLIN CANCER RES, vol. 11, 2005, pages 4627 - 4633
ref_type: npl
severity: background
ref_id: - KRUPKOVA ET AL., JOURNAL OF NUTRITIONAL BIOCHEMISTRY, vol. 37, 2016, pages 1 - 12
ref_type: npl
severity: background
ref_id: - J. PHARM. BIOMED. ANAL., vol. 56, 2011, pages 692 - 697
ref_type: npl
severity: background
ref_id: - CHEM. PHARM. BULL., vol. 62, no. 4, 2014, pages 328 - 335
ref_type: npl
severity: background
ref_id: - NUTRIENTS, vol. 8, 2016, pages E307
ref_type: npl
severity: background
ref_id: - LOURDES ET AL., J. AGRIC. FOOD CHEM., vol. 55, 2007, pages 8857 - 8863
ref_type: npl
severity: background
ref_id: WO2014055830A1
ref_type: patent
severity: background
ref_id: EP2263481A1
ref_type: patent
severity: background
ref_id: EP2263481
ref_type: patent
severity: background
ref_id: WO2014055830
ref_type: patent
severity: background
Final disposition: pending (2020-12-02)